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Lysophosphatidic acid (LPA) is present in abundance in serum resulting from platelet activation and is also found
in other biological ﬂuids. LPA controls numerous cellular responses and plays a role in specific functions such as
wound healing, especially in the skin. Nevertheless, its presence in the skin has never been investigated. Since re-
epithelialization occurs after blister rupture, we tested the presence of endogenous LPA in blister ﬂuid and in-
vestigated a possible mechanism for its biosynthesis and biological functions. Using a radioenzymatic assay, LPA
was detected in 33 blister ﬂuids originating from 24 bullous dermatoses, and at higher concentrations than in
plasma. In parallel, blister ﬂuids contained a lysophospholipase D (LPLD) activity but no detectable phospholipase
A2 activity. The expressions of the LPLD autotaxin (ATX) and of LPA1–receptor (LPA1-R) were greatly increased in
blister skin when compared with normal skin. Finally, LPA was found to have a positive effect on the migration of
cultured keratinocytes. These results show that LPA is present in blister ﬂuid synthesized by the LPLD ATX. Due
to its ability to enhance keratinocyte migration, LPA in blister ﬂuid could, via the LPA1-R, play an important role in
re-epithelialization occurring after blister rupture.
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Lysophosphatidic acid (LPA) is the simplest phospholipid
found in nature. It is present in abundance in serum result-
ing from platelet activation. LPA is also found in other bi-
ological fluids such as plasma (Baker et al, 2002) and ascite
fluids (Xu et al, 1998) of patients suffering from ovarian
cancer, aqueous humor, and lacrimal gland fluid (Liliom
et al, 1998), follicular fluid (Tokumura et al, 1999), saliva
(Sugiura et al, 2002), extracellular fluid of adipose tissue
(Valet et al, 1998), and arthritis inflammatory fluids (Four-
cade et al, 1995). It has been demonstrated that LPA may
be generated by various cells including cancer cells (Mer-
chant et al, 1991; Xu et al, 1998; Baker et al, 2002), fibro-
blasts (Fukami and Takenawa, 1992) and adipocytes (Valet
et al, 1998). Nevertheless, the precise cellular origin of LPA
in biological fluids still remains unclear (Gaits et al, 1997;
Pages et al, 2001). Furthermore, the pathways involved in
LPA production are still a matter of debate. There are two
main pathways: the phospholipase A2 (PLA2)-dependent
deacylation of phosphatidic acid (PA) and the lyso-
phospholipase D (LPLD)-dependent hydrolysis of lyso-
phosphatidylcholine (LPC) (Gaits et al, 1997; Pages et al,
2001; Aoki et al, 2002). It has been previously proved that
LPLD activity was involved in LPA production in fluids such
as rat plasma (Tokumura et al, 1998), human follicular fluid
(Tokumura et al, 1999), and in the extracellular medium of
adipocytes (Gesta et al, 2002). Umezu-Goto et al (2002),
Tokumura et al (2002), and Ferry et al (2003) purified LPLD
activity from bovine serum, human plasma, and adipocytes,
respectively, and demonstrated that it was caused by a
soluble form of autotaxin (ATX). ATX is a tumor cell mobility
factor, originally isolated from melanoma cell supernatants,
and belonging to the ecto-nucleotide pyrophosphatase/
phosphodiesterase family (Moolenaar, 2002). LPA acts via
interaction with specific G-protein-coupled receptors be-
longing to the endothelium differentiation gene family:
LPA1-receptor (LPA1-R: Edg-2), LPA2-receptor (LPA2-R:
Edg-4), and LPA3-receptor (LPA3-R: Edg-7) (Chun et al,
2002). Pharmacological specificity and tissue distribution
may differ from one subtype to another (Contos et al, 2000).
LPA controls numerous cellular responses such as prolifer-
ation, differentiation, migration, and apoptosis, and plays a
role in specific functions such as wound healing (Liliom et al,
1998; Sturm et al, 1998; Hines et al, 2000). LPA is involved in
the pathophysiology of arteriosclerosis (Siess, 2002), and
different conditions, such as cancers, are associated with
LPA production (Merchant et al, 1991; Xu et al, 1998; Baker
et al, 2002). Its precise mechanism of action, however, is
currently unknown. In the skin, it has been demonstrated
that LPA plays a role in tissue repair and regeneration proc-
esses. Using cultured human keratinocytes, Piazza et al
(1995) demonstrated that LPA induced proliferation and dif-
ferentiation. The fact that LPA is released from activated
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platelets (Eichholtz et al, 1993), as well as the presence of
active phospholipases in the skin (Maury et al, 2000;
Mazereeuw-Hautier et al, 2000), strongly supports this hy-
pothesis. This is also supported by the fact that topical
application of LPA to a wound model of mouse or rat skin
promotes wound healing (Demoyer et al, 2000; Balazs et al,
2001). Nevertheless, the presence of LPA has never been
investigated in the skin, during wound healing, or in other
situations. Since re-epithelialization of the underlying wound
bed occurs after blister rupture, we tested the presence of
endogenous LPA in blister fluid and investigated a possible
mechanism for its biosynthesis and biological functions in
various dermatoses.
Skin blisters (Diaz and Giudice, 2000) are formed as a
result of a breakdown of tissue integrity, with detachment of
cellular junctions and fluid accumulation. There are several
etiologies of blister formation (hypersensitivity, physical in-
jury, autoimmunity, hereditary, virus infection), and the blis-
ters can occur at different levels within the epidermis. The
blisters can be intraepidermal (eczema, burn, varicella-zos-
ter virus infection), or subepidermal (bullous pemphigoid,
toxic epidermal necrolysis, dystrophic epidermolysis bullo-
sa). Some biochemical features of blister fluid have already
been documented in succion blister. This fluid has been
qualified as a ‘‘filtrate’’ of serum since the concentration of
each compound was smaller than in the serum and was
dependent on its molecular weight (Volden et al, 1980).
Blister fluid also contains local products of cell injury and
inflammation (Grando et al, 1989a; Ono et al, 1995; D’Auria
et al, 1999). The presence of LPA in blister fluid has never
been demonstrated.
Results
LPA is present in blister ﬂuids In order to determine the
presence of LPA in blister fluid, LPA was quantified using a
radioenzymatic assay. Micromolar (mean  SEM, 0.60 
0.0087 mM, range 0–1.90) concentrations of LPA were
detected in blister fluids originating from all patients except
for one, who was suffering from toxic epidermal necrolysis.
The results for LPA concentrations are shown in Table I. No
statistical correlation could be established between LPA
concentration and the following characteristics, respective-
ly: age (Spearman, p¼0.33), sex (Kruskal–Wallis, p¼0.95),
aetiology of bullous diseases (Kruskal–Wallis, p¼0.054),
blister duration (Spearman, p¼ 0.41), indirect immunofluo-
rescence (Kruskal–Wallis, p¼ 0.7), eosinophilia (Kruskal–
Wallis, p¼0.69) or steroid treatment for bullous pemphigoid
(Kruskal–Wallis, p¼0.07).
We wanted to determine whether LPA present in blister
fluid originated from plasma or was produced locally within
the blister. We therefore compared LPA concentration in
blister fluid to LPA concentration in plasma originating from
the same individuals (n¼2). We found that plasma con-
centrations were 9-fold lower than blister fluid concentra-
tions (plasma: 0.07 mM vs blister 0.4 mM and 0.064 mM vs
1.2 mM for the two patients, respectively) (data not shown).
This result clearly shows that LPA is produced in blister fluid
and does not originate from plasma. In blister fluid, LPA was
present in the supernatants and absent in the pellet after
ultra-centrifugation and cell removal (data not shown), in-
dicating LPA solubility.
Since LPA is present in blister fluid, we decided to in-
vestigate the presence of two possible precursors: PA and
LPC. The amount of PA and LPC present in blister fluids
(n¼5 and 10, respectively) was found to be 1.1  0.2 and
2.8  0.2 mM, respectively (mean  SEM). These results in-
dicate that blister fluid not only contained LPA but also its
precursors: PA and LPC.
Metabolic origin of LPA in blister ﬂuid We then decided
to elucidate the metabolic origin of LPA produced in blister
fluid. It has been demonstrated in other tissues that LPA
could be produced by a soluble extracellular LPA synthesis
activity (Tokumura et al, 1999; Gesta et al, 2002). In order to
test the presence of such an activity in blister fluids, incu-
bation of the fluids was performed at 371C for 6 h. After
incubation, the concentration of LPA had doubled (mean
SEM: 1.70  0.72 vs 3.40  1.05 mM) (n¼5) (Wilcoxon,
po0.05) (Fig 1), showing the presence of a soluble extra-
cellular LPA synthesis activity. We then studied the two
major pathways possibly involved in soluble LPA synthesis:
the PLA2-dependent deacylation of PA, and the LPLD-
Table I. Lysophosphatidic acid (LPA) concentrations in blister ﬂuids
Bullous dermatoses No. of patients No. of samples
LPA (lM)
Mean (  SEM) Range
Eczema 3 4 0.8  0.3 0.2–1.6
Burn 5 5 0.9  0.27 0.4–1.9
Bullous pemphigoid 10 10 0.4  0.09 0.2–1.2
No treatment 3 3 0.68  0.26 0.41–1.2
Under steroid treatment 7 7 0.32  0.04 0.16–0.5
Varicella-zoster virus infection 2 2 1.1  0.42 0.7–1.5
Toxic epidermal necrolysis 3 11 0.5  0.15 0–1.6
Dystrophic epidermolysis bullosa 1 1 0.2
Quantification of LPA was performed using a radioenzymatic assay as described in Materials and Methods.
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dependent hydrolysis of LPC (Gaits et al, 1997; Pages et al
2001; Aoki et al, 2002). From the same five patients, we
showed that the intrinsic LPA synthesis activity was not mod-
ified after 6 h of incubation at 371C with quinacrine (Fig 1). In
conjunction, no PLA2 activity could be detected in blister
fluids (n¼32), except for one patient suffering from toxic
epidermal necrolysis (data not shown). In contrast, after 6 h
of incubation at 371C with phenanthrolin, LPA synthesis
activity was completely abolished (n¼5) (Fig 1). In parallel,
LPLD activity was 0.018  0.005 pmol per min per mg pro-
tein, range 0–0.9, (n¼10) (data not shown).
Since LPLD activity can be catalyzed by ATX (Tokumura
et al, 2002; Umezu-Goto et al, 2002; Ferry et al, 2003), the
expression of ATX transcripts was investigated in blister
skin using real-time RT-PCR, and was compared with nor-
mal skin originating from the same individuals (n¼4). As
shown in Fig 2, ATX mRNA was found in blister skin and was
approximately four times more abundant than in normal skin
(Wilcoxon, po0.05). This result strongly suggested that ATX
might be responsible for LPLD activity in blister fluid, and
that skin expression of ATX was induced during the forma-
tion of the blister.
Skin expression of LPA-receptors The biological re-
sponses of LPA being mediated by specific receptors (Con-
tos et al, 2000; Chun et al, 2002), the expression of these
receptors was also investigated in blister skin and com-
pared to normal skin originating from the same individuals
(n¼ 4). As shown in Fig 2, mRNA of the three LPA receptor
subtypes (LPA1-R, LPA2-R, LPA3-R) was detected in blister
skin. When compared with normal skin, LPA1-R mRNA from
blister skin was 6.42 times more abundant (Wilcoxon,
po0.05), whereas LPA2-R mRNA and LPA3-R mRNA were
4.30 and 2.50 times (not statistically significant (Wilcoxon,
p¼0.14 and 0.15)) less abundant, respectively. In parallel,
no significant alteration in the level of hypoxanthine phos-
phoryl transferase mRNA (used as a housekeeping gene)
was observed. These results showed that blister formation
is accompanied by the regulation of LPA receptors expres-
sion, and particularly by a consistent upregulation of the
LPA1-R subtype.
Effects of LPA on HaCaT cells’ migration In the literature,
LPA has been involved in wound healing by inducing ker-
atinocyte proliferation and differentiation. Since migration
takes part in wound healing and LPA induces epithelial cells
migration (Liliom et al, 1998; Sturm et al, 1998; Hines et al,
2000), we decided to investigate the effect of LPA on ker-
atinocyte migration.
LPA was found to have a positive concentration-de-
pendent effect on keratinocyte migration. The effect in-
creased according to LPA concentrations and was
statistically different from control at concentrations of 1
mM or above, showing a plateau at 2 mM (Fig 3) (Spearman,
Figure 1
Soluble extracellular lysophosphatidic acid (LPA) synthesis activity
in blister fluid and influence of quinacrine and phenanthrolin. LPA
was quantified in blister fluids from five patients, before (t0) and after 6 h
(t6 h) incubation at 371C without (cont) or with quinacrine (quin) at
100 mM or phenanthrolin (phen) at 100 mM. Values are means  SEM
from four independent repetitive assays realized for each patient.
Statistical significance was considered when po0.05 (), ns, not
statistically significant.
Figure2
Expression of lysophosphatidic acid (LPA) receptor subtypes and
autotaxin (ATX) in skin biopsies using real-time PCR. Normal skin
(filled bars) and blister skin (unfilled bars) were both obtained from the
same individuals suffering from bullous dermatoses (four patients). To-
tal RNA was isolated and mRNA encoding LPA1-receptor (LPA1-R),
LPA2-receptor (LPA2-R) and LPA3-receptor (LPA3-R), autotaxin (ATX),
and hypoxanthine phosphoribosyl transferase (HPRT) was quantified
using real-time PCR as described in Materials and Methods. Values are
means  SEM from four independent repetitive assays realized for
each patient. mRNA in normal skin was compared to RNA in blister
skin (po0.05).
Figure3
Effect of lysophosphatidic acid (LPA) on keratinocyte migration.
LPA was solubilized in phosphate-buffered saline using 1% bovine
serum albumin prior to addition of RPMI-1% bovine serum albumin.
HaCaT cells were treated or not (control (cont): RPMI containing 1%
bovine serum albumin) to increased concentrations of LPA. Cell mi-
gration was assessed using modified Boyden chambers as described
in Materials and Methods. The migration was expressed as a migration
index, and represented the percentage of migrated cells with LPA
compared to the percentage of migrated cells with the control. Values
are means  SEM from three independent repetitive experiments
realized with three independent pools of cells. The migration index
obtained after treatment by various concentrations of LPA was com-
pared with migration index of the control (po0.05).
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po0.05). This result suggests that LPA in blister fluid en-
hances keratinocyte migration.
Discussion
This work shows the presence of LPA in blister fluid. LPA is
a bioactive phospholipid mediating its activity via stimula-
tion of specific G-protein-coupled receptors.
Several authors have concluded that LPA plays a role in
skin wound healing (Piazza et al, 1995; Demoyer et al, 2000;
Balazs et al, 2001) by enhancing the proliferation and dif-
ferentiation of keratinocytes. Sauer et al (2004) showed that
LPA mediates keratinocyte growth arrest and chemotaxis.
The effects of LPA on wound healing have also been studied
in intestinal epithelial cells (Liliom et al, 1998; Sturm et al,
1998; Hines et al, 2000), where LPA induced migration and
proliferation. After blister formation, re-epithelialization of
the underlying wound bed occurs after blister rupture. Re-
epithelialization involves a sequential program of events in
order to close a wound as quickly as possible (Yamaguchi
and Yoshikawa, 2001). An increase in the rate of migration
of keratinocytes over the wounded area, as well as an in-
crease in the rate of proliferation of basal cells, occurs. Si-
multaneously, cells migrate into the upper epidermal layers,
ultimately undergoing terminal differentiation to form the
stratum corneum and repairing the barrier function of the
skin. The concentrations of LPA found in our study (mean 
SEM, 0.60  0.0087 mM, range 0–1.90) were high enough to
induce potential biological effects since the usual EC50 are
between 5 and 150 nM (Pages et al, 2001). Therefore, LPA
may take part in wound healing via effects on cell prolifer-
ation, differentiation, and migration. This hypothesis is
supported by our data showing that LPA increases
keratinocytes migration in culture, and that the skin ex-
presses LPA receptor subtypes (LPA1-R, LPA2-R, LPA3-R).
Since Amano et al (2004) demonstrated that LPA stimulates
laminin 5 expression, the effect of LPA on migration could
be mediated by this protein, known to be involved in the
adhesion and migration of keratinocytes. Whereas the spe-
cific contribution of each LPA-receptor subtype in the bi-
ological activity of LPA in keratinocytes remains to be
determined, its is interesting to notice that the expression of
the LPA1-R subtype was substantially increased in skin
from blisters when compared to normal skin, whereas the
expression of LPA2-R and LPA3-R was not altered or was
even decreased. Even if the underlying mechanisms remain
unclear, upregulation of the LPA1-R suggests that this re-
ceptor plays a predominant role in the biological activity of
LPA in skin during blister formation. Therefore, LPA1-R
might represent a pharmacological target for skin wound-
healing therapy.
In our study, LPA was present in blister fluids originating
from all bullous dermatoses but no correlation could be es-
tablished between the level of LPA and the characteristics
of the blister. This result may be explained by the small
number of cases and their heterogeneity, or could mean that
LPA is a consequence of the blister rather than being di-
rectly involved in the pathogenesis of the bullous disease.
LPA concentration in blister fluid (0.6 mM) was close to
that found in other biological fluids such as saliva (Sugiura
et al, 2002), lacrimal gland, and aqueous humor (Liliom et al,
1998) (0.785, 1, and 0.2 mM, respectively), and higher than in
plasma (0.08 to 0.2 mM) (Tokumura et al, 1998). This last
observation suggests that, in contrast to what was de-
scribed for other blister fluid constituents, such as fatty
acids, organic acids, and aminoacids, LPA does not result
from a filtration of plasma but rather from a local synthesis.
This hypothesis is supported by the demonstration of the
presence of a LPA synthesis activity, as well as of LPA
precursors (PA and LPC) in blister fluid.
Two major pathways might be involved in LPA synthesis:
the PLA2-dependent deacylation of PA and the LPLD-de-
pendent hydrolysis of LPC. Since LPA synthesis activity in
blister fluid is not blocked by quinacrine, we excluded the
possibility of the involvement of PLA2 in LPA synthesis in
blister fluid. This hypothesis was also supported by the ab-
sence of detectable PLA2 activity in blister fluid. In contrast,
our data strongly suggest that LPLD activities are respon-
sible for endogenous LPA formation since it is blocked by
phenanthrolin, an ion chelator previously demonstrated
to inhibit LPLD activity in plasma and adipose tissue
(Tokumura et al, 1998; Gesta et al, 2002). Furthermore, an
easily measurable LPLD activity was found in blister fluid.
Based on the literature, the only enzyme demonstrated to
be able to catalyze a soluble LPLD activity is ATX, sug-
gesting that this enzyme could be responsible for LPA syn-
thesis in blister fluid.
This is in accordance with the demonstration of a relatively
high level of expression of ATX in the skin from blister, com-
pared with human adipose tissue where LPA is particularly
abundant (mRNA/18SRNA: 13.35 vs 40) (Boucher et al, 2005).
Interestingly, ATX expression was more abundant in blis-
ter skin than in normal skin. Blister formation can be con-
sidered as tissue injury where cell composition and
functions are altered, leading to the release of several com-
ponents including mediators of inflammation (Grando et al,
1989a; Ono et al, 1995; D’Auria et al, 1999), enzymes such
as tryptases, myeloperoxydases, or proteases, and their
inhibitors (Grando et al, 1989b; D’Auria et al, 2000). This
type of skin injury could be responsible for the upregulation
of ATX expression and therefore could lead to the synthesis
of LPA. Such a relation between tissue injury and LPA pro-
duction has been previously reported. LPA was indeed
found to be released by epithelial cells in aqueous humor
after corneal injury (Liliom et al, 1998) or during intracranial
hematoma in a pig model (Tigyi et al, 1995).
In conclusion, LPA is produced in blister fluid by an LPLD
activity. Our data suggest that ATX is the source of LPLD
activity. LPA in blister fluid might act via LPA-receptors, es-
pecially LPA1-R, and have a role in skin wound healing, in
particular, via an effect on keratinocyte migration.
Since ATX is involved in LPA production, this enzyme
could represent an interesting target to enhance skin wound
healing.
Materials and Methods
Collection of blister ﬂuid and blood Thirty-three samples from
24 patients (13 females and 11 males; mean age was 53.96 
30.44 y, range 2–90 y) suffering from different bullous dermatosis
were investigated between December 2001 and November 2002.
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There were six different etiologies of bullous dermatoses: bullous
pemphigoid (n¼ 10), second-degree burn (n¼ 5), eczema (n¼ 3),
toxic epidermal necrolysis (n¼ 3), varicella–zoster virus infection
(n¼ 2), and dystrophic epidermolysis bullosa (n¼ 1). The medical
ethical committee of the University of Toulouse approved all the
described studies. The subjects of our study gave their informed
written consent, and investigations were carried out in accordance
with the Declaration of Helsinki as revised in 2000 (http://
www.wma.net/e/policy/b3.htm). Some fluids were collected at
several clinical stages from some patients suffering from toxic ep-
idermal necrolysis (n¼ 2) or eczema (n¼ 1). The final diagnosis was
based on anamnesis, clinical manifestations, routine histology, de-
tection of autoantibodies using direct and indirect imunofluores-
cence, and viral culture and serologies. Collection of fluid was
realized before the beginning of any treatment, except for seven of
ten patients with bullous pemphigoid who were already under
steroid therapy (topical application of Diprolene (clobetasol) 30 g
per D, n¼ 2 or oral route of Solupred (prednisolone) (0.50–1.50 mg
per kg per D, n¼ 5). The blisters originating from patients under
steroid therapy were only used for LPA quantification and sPLA2
activity experiments, and not for the determination of the metabolic
origin of LPA. The identification of the different types of blisters
used for the various experiments is shown in Table II. The blisters
were punctured with a needle, and the fluid was collected in a
syringe. In order to determine whether LPA was soluble or asso-
ciated with cell particles, fluids were subjected to ultra-centrifu-
gation (100,000  g for 5 min at 371C). Fluids were immediately
stored at 201C until further analysis.
In cases of requirement of blood sample for medical reasons,
human plasma was collected in ethylenediaminetetraacetic acid
(EDTA)-conditioned tubes.
Collection of skin biopsies Eight biopsies were taken between
January and June 2003 from four additional patients (three females
and one male, mean age 81 y, range 77–91 y) suffering from bull-
ous dermatosis (Table II). Two biopsies were taken from each pa-
tient: one containing the entire blister, ‘‘blister skin’’, and one
containing the uninvolved skin, ‘‘normal skin’’. Biopsies were im-
mediately frozen in liquid nitrogen and stored at 801C until further
analysis.
LPA quantiﬁcation in blister ﬂuid Quantification of LPA was
performed using a radioenzymatic assay as described previously
(Saulnier-Blache et al, 2000). In short, lipids contained in blister
fluids were extracted with 1 volume of 1-butanol followed by
evaporation of the solvent under nitrogen. In the presence of [14C]
oleoyl-CoA, recombinant rat LPA acyl-transferase selectively cat-
alyzes the transformation of LPA into [14C] PA. Products of the
reaction were separated by one-dimensional thin-layer chroma-
tography and autoradiographed. Each spot of [14C] PA was
scraped off and counted with 3 mL scintillation cocktail. Radioac-
tivity was converted to nanomoles, and the concentration of LPA
was calculated. We used 1-oleoyl-LPA (Sigma-Aldrich, St Louis,
Missouri) as a standard (Saulnier-Blache et al, 2000). This method
has been previously validated as a quantitative assay (Saulnier-
Blache et al, 2000). We verified that the assay was also quantitative
using blister fluids.
In order to determine the presence of intrinsic LPA synthesis
activity and its metabolic pathway (PLA2 or LPLD), quantification of
LPA was also performed after 6 h of incubation of blister fluid at
371C with or without 100 mM of quinacrine (Biomol, Plymouth
Meeting, Pennsylvania) an inhibitor of PLA2 (McCrea et al, 1985), or
100 mM of phenanthrolin (Sigma-Aldrich), previously demonstrated
to inhibit LPLD activity (Tokumura et al, 1998; Gesta et al, 2002).
PA and LPC quantiﬁcation in blister ﬂuid As previously de-
scribed (Gesta et al, 2002), the amount of PA and LPC present in
blister fluid was determined by quantifying the amount of LPA
generated after treatment by pancreatic PLA2 or bacterial PLD,
respectively. Incubation was realized at 371C for 90 min with pan-
creatic PLA2 at 1.92 UI per mL (Sigma-Aldrich), or bacterial PLD
from Streptomyces chromofuscus at 1 UI per mL (Sigma-Aldrich).
This method has been previously validated as a quantitative assay
(Saulnier-Blache et al, 2000). We verified that the assay was also
quantitative using blister fluids.
Assay for PLA2 activity in blister ﬂuids PLA2 activity was de-
termined by measuring the rate of release of pyrenyldecanoic acid
from the pyrene-labeled phospholipid 1-hexadecanoyl-2-(1-pyre-
ne-decanoyl-)-sn-glycero-3-phosphoglycerol, ammonium salt (In-
vitrogen, Carlsbad, California), as previously described (Radvanyi
et al, 1989), with minor modifications. Blister fluid samples of 10 mL
were incubated for 1 h at room temperature with 1 mL reaction
buffer containing 50 mM Tris-HCl (pH 7.5), 100 mM NaCl, 1 mM
Table II. Identiﬁcation of the different types of blister ﬂuid
used for the various experiments
Type of experiments
Type of bullous dermatoses
studied
LPA quantification in blister fluids All type of bullous dermatosis
LPA quantification in plasma Lyell (n¼ 2)
PA quantification Lyell (n¼ 2)
Bullous pemphigoid (n¼ 2)
Burn (n¼ 1)
LPC quantification Lyell (n¼ 3)
Bullous pemphigoid (n¼ 2)
Burn (n¼ 3)
Eczema (n¼1)
Varicella-zoster virus infection
(n¼1)
LPA synthesis activity Lyell (n¼ 2)
Bullous pemphigoid (n¼ 2)
Burn (n¼ 1)
Inhibition of LPA synthesis
activity by quinacrine
Lyell (n¼ 2)
Bullous pemphigoid (n¼ 2)
Burn (n¼ 1)
PLA2 activity All type of bullous dermatosis
Inhibition of LPA synthesis
activity by phenanthrolin
Lyell (n¼ 2)
Bullous pemphigoid (n¼ 2)
Burn (n¼ 1)
LPLD activity Lyell (n¼ 3)
Bullous pemphigoid (n¼ 2)
Burn (n¼ 3)
Eczema (n¼1)
Varicella-zoster virus infection
(n¼1)
Real-time PCR Bullous pemphigoid (n¼ 3)
Burn (n¼ 1)
The blisters originating from patients under steroid therapy were only
used for LPA quantification and PLA2 activity experiments, and not for the
rest of the experiments.
n, number of patients; LPA, lysophosphatidic acid; PA, phosphatidic
acid; LPC, lysophosphatidylcholine; PLA2, phospholipase A2; LPLD, lys-
ophospholipase D.
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EDTA, 10 % (wt/vol) fatty acid-free bovine serum albumin (BSA),
and the substrate (final concentration 2 mM). The reaction was in-
itiated by the addition of 10 mM CaCl2. This method has been
previously validated as a quantitative assay (Radvanyi et al, 1989).
We verified that the assay was also quantitative using blister fluids.
Fluorescence measurements were performed with a spectrofluoro-
meter (SFM 25 Kontron; Kontron, Downers Grove, Illinois) at exci-
tation and emission wavelengths of 345 and 398 nm, respectively.
Measurement of LPLD activity in blister ﬂuid LPLD activity was
measured by conversion of radiolabeled LPC into radiolabeled LPA
as previously described (Gesta et al, 2002) with minor modifica-
tions. A solution of [14C] palmitoyl-lysophosphatidylcholine (NEN,
55.8 mCi per mmole) at 0.0025 mCi per mL in DMEM supplemented
with 1% fatty acid-free BSA was first prepared, and 20 mL of this
solution was incubated with 500 mL of blister fluid plus 1 mL of
sodium orthovanadate 0.5 mM for 90 min at 371C. At the end of the
incubation period, phospholipids were extracted with 500 mL of 1-
butanol, evaporated, spotted on a silica gel 60 TLC glass plate
(VWR, West Chester, Pennsylvania), and separated using CHCI3/
MeOH/NH4OH (60/35/8) as a migration solvent. The plate was au-
toradiographed overnight at 801C using a Biomax-MS film (Ko-
dak, Rochester, New York) in order to localize [14C]LPA spots,
which were scraped off and counted with 3 mL of scintillation
cocktail. Activity was expressed as pmol [14C]LPA released per min
per mg of protein. Tokumura (Tokumura et al, 1998) validated the
quantitative nature of the assay. In our study, we verified that the
assay was also quantitative using blister fluids.
Expression of LPA-receptors and ATX in skin biopsies by real-
time RT-PCR We studied the expression of LPA-receptors and
ATX using real-time PCR, as previously validated by Moniotte et al
(2001). Total RNA was isolated from skin biopsies using the RNA
STAT-60 kit (AMS Biotechnology, Abington, Oxon, UK) and Rneasy
mini protocol for RNA Cleanup (Quiagen, Valencia, California). Total
RNA (1 mg) was reverse transcribed for 60 min at 371C using the
Superscript II reverse transcriptase (Invitrogen) in the presence of
random hexamers. A minus RT reaction was performed in con-
junction, as a control, to ensure the absence of genomic DNA
contamination. Real-time RT-PCR was performed starting with
26 ng cDNA with 300 nM (human LPA2-R) or 900 nM (human ATX,
human LPA1-R, human LPA3-R, and human hypoxanthine phos-
phoribosyl transferase as a control) concentrations of both sense
and antisense primers in a final volume of 25 mL, using the SYBR
green TaqMan Universel PCR Master Mix (Applied Biosystems,
Forster City, California). Fluorescence was monitored and analyzed
in a GeneAmp 7000 detection system instrument (Applied Biosys-
tems). Analysis of the 18S ribosomal RNA was performed in con-
junction with the use of the ribosomal RNA control taqman
assay kit (Applied Biosystems) in order to normalize gene expres-
sion. Results were expressed according to the dCT method as
2(Ct18SCtgene), where Ct corresponds to the number of cycles
needed to generate a fluorescent signal above a predefined
threshold (Moniotte et al, 2001).
Primer design was optimized by using the Primer Express soft-
ware (Perkin Elmer Life Sciences, Boston, Massachusetts). The
oligonucleotides used for these experiments are shown in Table III.
Cell migration assay of keratinocytes HaCaT cells (a gift from
Fusenig, Heidelberg, Germany), a spontaneously transformed, non-
tumorigenic human keratinocyte cell line, were cultured in RPMI
164 (Gibco, Langley, UK) with 10% fetal bovine serum at 371C, with
5% CO2. After confluence, the medium was changed to a medium
without serum for 24 h. Cell migration assays were performed in
modified Boyden chambers containing 8–12 mm pore size uncoated
polycarbonate membranes (Poretics Osmonic, Livermore, Califor-
nia). LPA was solubilized in phosphate buffered saline containing
1% BSA. The lower chambers were filled with various concentra-
tions of LPA (0–5 mM) in RPMI containing 1% BSA, or with human
epidermal growth factor (Sigma-Aldrich) (35 ng per mL in RPMI
containing 1% BSA) as a positive control (Barrandon and Green,
1987), or with the medium alone (RPMI containing 1% BSA) as a
negative control. The upper chambers were filled with cells in sus-
pension in RPMI containing 1% BSA (1  106 per mL). After 45 min
of incubation at 371C, the filter was removed and the top surface
of the membrane was wiped to remove non-migrating cells. The
membrane was fixed in ethanol and stained with RAL 555 fast-
staining kit (VWR, West Chester, Pennsylvania). The migration was
evaluated by counting the stained migrating cells at the bottom
surface of the membrane by light microscopy (Axioskop 20, Zeiss
(Thornwood, New York)). At least three different fields were eval-
uated, and the average was calculated. The migration was ex-
pressed as a migration index and represented the percentage of
migrated cells with LPA compared with the percentage of migrated
cells with medium alone (RPMI 1% BSA).
Protein determination Protein concentration was determined by
the DC Protein assay (Biorad, Hercules, California) with BSA as the
standard.
Statistical analysis Data were expressed as mean  SEM from
four independent repetitive experiments realized for each patient’s
sample of blister fluid or skin biopsy. For experiments of migration,
three independent repetitive experiments were performed using
three independent pools of cells. Statistical analysis was per-
formed using SAS 6.0 and non-parametric tests (Wilcoxon
matched-pairs signed-rank test, Spearman’s rank-order correla-
tion coefficient, and Kruskal–Wallis one-way of variance by ranks).
Statistical significance was considered when po0.05.
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Table III. Oligonucleotides used to study the expression of
ATX and LPA-receptors by RT-PCR
Gene Oligonucleotide sequences
Human ATX
Sense 50-GGACCAACATCTCCGGATCTT-30
Antisense 50-GGAGGTCCAGCCTCTTGAAGT-30
Human LPA1-R
Sense 50-TGGGCCATTTTCAACTTGGT-30
Antisense 50-TCTGGCGAACATAGCCAAAGA-30
Human LPA2-R
Sense 50-TCATCATGGGCCAGTGCTACT-30
Antisense 50-GTGGGAGCTGAGCTCTTTGC-30
Human LPA3-R
Sense 50-TGGGCCATCGCCATTTT-30
Antisense 50-GAGCAGGCAGAGATGTTGCA-30
Human hypoxanthine phosphoribosyl transferase
Sense 50-TGACACTGGCAAAACAATGCA-30
Antisense 50-GCTTGCGACCTTGACCATCT-30
ATX, autotaxin; LPA1-R, LPA1-receptor; LPA2-R, LPA2-receptor;
LPA3-R, LPA3-receptor.
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